Sun Pharmaceutical reported a 10% revenue increase for Q1 FY27, driven by strong India sales and innovative medicines. Despite this growth, the company faces pressure in its U.S. generics business due to price erosion and increased competition. Investors are tracking how ongoing R&D investments and the upcoming Organon acquisition impact future profit margins.
Sun Pharmaceutical Industries Ltd. reported a 10% year-on-year rise in consolidated revenue, reaching ₹15,183 crore for the quarter ended June 2026. This performance outperformed the company's own high single-digit growth projections for the fiscal year, though management maintained its overall annual outlook.
Domestic Growth and Innovative Drugs
India formulations remained a primary engine for the company, contributing 36% of total revenue. Sales in this segment grew by 16% to ₹5,475 crore. The company credited this momentum to strong demand in cardiovascular, central nervous system, and gastro-ortho therapy areas. Volume growth accounted for nearly 40% of this increase, while new product launches contributed 20%. Notably, Sun Pharma has expanded its footprint in the semaglutide market, establishing itself as the only Indian manufacturer to provide a semaglutide auto-injector.
Innovative medicines also provided a boost, with global revenue rising 12.8% to $351 million. Key contributors to this segment included products like Ilumya, Odomzo, and Cequa. While emerging markets showed 15.4% growth in rupee terms, dollar-denominated growth slowed to 4%, reflecting economic and geopolitical challenges in certain regions.
Challenges in the U.S. Market
In contrast to the domestic performance, the U.S. formulations business recorded a 9.7% decline, with revenue falling to $427 million. This weakness was primarily attributed to sustained price erosion, particularly in Lenalidomide, and intense market competition. The company is pinning hopes on its new product, Leqselvi, which is currently seeing higher prescription rates as it gains physician acceptance.
Margin Dynamics and Future Outlook
Consolidated EBITDA margins contracted by 133 basis points year-on-year to 28.1%. This pressure resulted from higher acquisition-related costs, lower foreign exchange gains, and elevated spending on new product launches. However, gross margins improved by 95 basis points to 80.5%, supported by a shift toward a more profitable product mix.
The company is working toward the closure of its Organon acquisition in the fourth quarter of fiscal year 2027. While the immediate financial contribution from this portfolio is expected to be modest, analysts from JM Financial suggest the deal could eventually double annual free cash flow by FY29. Moving forward, investors should monitor the integration costs of this acquisition, the company’s ability to manage R&D spending, and the stabilization of pricing in the U.S. generic drug market.